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Abstract
Background: Physicians often administer corticosteroids for the treatment of fluid and vasoactive infusion
dependent pediatric shock. This use of corticosteroids is controversial, however, and has never been studied in a
pediatric randomized controlled trial (RCT). This pilot trial will determine the feasibility of a larger RCT on the role of
corticosteroids in pediatric shock.
Methods/design: Steroids in Fluid and/or Vasoactive Infusion Dependent Pediatric Shock (STRIPES) is a pragmatic,
seven-center, double-blind, pilot RCT. We aim to randomize 72 pediatric patients with fluid and vasoactive infusion
dependent shock to receive either hydrocortisone or a saline placebo for 7 days or until clinical stability, whichever
occurs first. The primary outcome of this pilot trial is the feasibility of recruitment, defined as the number of
patients enrolled over a 1-year period. Secondary outcomes include the frequency of, and reasons for, open-label
steroid use, protocol adherence, incidence of mortality and corticosteroid-associated adverse events, time to
discontinuation of inotropes, and feasibility of blood sampling.
Discussion: Corticosteroids are used for the treatment of pediatric shock without sufficient evidence to support
this practice. While there is a scientific rationale and limited data supporting their use in this setting, there is also
evidence from other populations suggesting potential harm. The STRIPES pilot study will assess the feasibility of a
larger, much needed trial powered for clinically important outcomes.
Trial registration: ClinicalTrials.gov: NCT02044159
Background
Fluid and vasoactive infusion dependent shock is a
critical form of cardiovascular failure affecting approxi-
mately 20,000 North American children annually. This
form of severe shock results in approximately 5 % of
pediatric intensive care unit admissions [1] and may lead
to multi-organ failure with significant morbidity [2, 3]
and a 2–10 % mortality rate [4, 5]. The role of cortico-
steroids in pediatric patients with severe septic shock
who are not responding to fluids and vasoactive infu-
sions has been widely debated for more than 40 years,
and current clinical research evidence neither supports
nor refutes this practice [6, 7].
The American College of Critical Care Medicine states
that “fluid and vasoactive infusion dependent shock
results from inadequate cellular corticosteroid activity
for the severity of the patient’s illness” [8]. This condi-
tion has been referred to as “relative adrenal insuffi-
ciency” or “critical illness related adrenal insufficiency”
[9, 10] and is a complex condition resulting from a
variety of mechanisms, making it challenging to define
and diagnose [10, 11]. Lack of sufficient cortisol leads to
hemodynamic instability through decreased myocardial
contractility, increased vasodilatation, and/or capillary
leak syndrome [12, 13]. Thus, there is some scientific
rationale for corticosteroid use in this population;
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however, the small numbers of observational studies and
randomized controlled trials on this subject have reported
conflicting conclusions.
Eight small randomized controlled trials (RCTs) of
corticosteroids in pediatric shock have included a total
of 489 patients [2, 3, 14–19]. Each study enrolled fewer
than 100 patients and had methodological limitations,
and all were conducted in developing nations with a
focus on dengue shock. Two studies demonstrated a
mortality benefit from corticosteroids in dengue shock
syndrome [14, 18], and the remaining trials were not
adequately powered to determine the effect of cortico-
steroids on clinically relevant outcomes. None of the
trials were conducted since the publication of the Sur-
viving Sepsis Campaign guidelines [20], making them
difficult to interpret in the context of current shock man-
agement. Additionally, heterogeneity in steroid agents,
dosing regimens, and duration of therapy make interstudy
comparisons difficult. Similarly, the two largest RCTs
conducted involving critically ill adults also demonstrated
contradictory results [21, 22].
The potential adverse effects of corticosteroids in
pediatric shock have not been rigorously evaluated. Re-
cent observational studies suggest that corticosteroid
therapy in this population may increase hyperglycemia
and secondary infections, suppress adaptive immunity,
and increase mortality [23–25]. An adult RCT also sug-
gested an increase in secondary infections and mortality
with the use of corticosteroids in shock [21].
Given the poor methodological quality of the existing
pediatric RCTs, the variability of administration proto-
cols studied, contradictory results from adult trials, and
the lack of information on potential adverse effects, it
has been difficult to develop evidence-based guidelines
for steroid use in critically ill children with fluid and
vasoactive infusion dependent shock. Hydrocortisone is
the most commonly used corticosteroid in large ran-
domized controlled shock trials [21, 22] and is currently
the most commonly used corticosteroid for treatment of
pediatric shock [26]. However, the management of these
patients remains highly variable with many critical care
physicians having strongly held beliefs both for and
against steroid use [27, 28].
We therefore propose a pragmatic, parallel group,
randomized, placebo-controlled pilot trial of hydrocorti-
sone for the treatment of pediatric fluid and vasoactive
infusion dependent shock. The specific objectives of the
STRIPES (Steroids in Fluid and Vasoactive Infusion
Dependent Pediatric Shock) pilot study are to estimate
the rate of patient recruitment and understand barriers
to recruitment, assess the appropriateness of our eligibil-
ity criteria for a full trial, assess adherence to the treat-
ment protocol, and assess the feasibility of collecting
and shipping blood samples.
Methods/design
This protocol adheres to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist (see checklist, Additional file 1). A summary of
the protocol is provided in Table 1.
Study setting
The STRIPES pilot study will recruit patients from the
emergency department (ED), pediatric ward, and/or
pediatric intensive care unit (PICU) of seven academic
pediatric centers in Canada (a list of participating study
sites is available on ClinicalTrials.gov).
Patient enrollment
ICU-based clinical research assistants will screen pediatric
ICU patients for eligibility criteria which include being a
patient with fluid and vasoactive infusion dependent shock
who has received inotropic support for at least 1 h, and no
more than 6 h, within their first 24 h of PICU admission.
This short period for recruitment is necessary as shock is
a progressive process characterized by an early compen-
sated phase in which adaptive mechanisms maintain
blood pressure and tissue perfusion, an uncompensated
phase where these mechanisms fail but the patient may
still respond to therapeutic interventions, and a final irre-
versible stage where shock progresses to permanent organ
and tissue injury and even death [29]. It is critical that any
potential therapy, including corticosteroids, be provided
early, which is why we have chosen a 6-h cut-off for
enrollment. The rationale for this time window therefore
is to enroll patients early in shock when steroids may have
the potential to prevent or reverse end-organ injury, prior
to the stage of advanced or irreversible shock. The detailed
inclusion and exclusion criteria are summarized in Table 2.
Eligible patients will be identified in the ED and PICU by
nurses, attending physicians, and trainees at participating
sites at the time the patient is started on a vasoactive agent
(see Fig. 1 for the protocol flow diagram).
Consent
The initial resuscitation of a pediatric patient is a highly
stressful situation during which parents are often unable
to contemplate involvement in a research trial and/or
may not be available within the time frame required by a
given study. Therefore, as per the Canadian Tri-Council
guidelines [30], we will be seeking deferred consent
through the Research Ethics Board (REB) applications.
Informed consent will be obtained from the legal guardian
of all patients; however, when the deferred consent model
is employed, informed consent will be obtained following
enrollment. Using this model, children will be enrolled
and randomized when they are determined to be eligible
for the study. A member of the local study team will
approach the legal guardian for written informed consent
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to continue study participation as soon as possible after
enrollment. If consent is obtained, the patient will remain
in the study. If consent is denied, the legal guardian and
patient will be provided the option of having patient data
and the blood sample destroyed. In centers where a
deferred consent model is not approved by the REB,
informed consent will be sought from the legal guardian
in writing or by telephone, after which the patient will be
enrolled and randomized. Legal guardians may provide
consent for data collection and drug administration with
or without blood sampling.
Randomization
Randomization will employ a password-protected, web-
based system. Patients will be randomized in a 1:1 ratio
using random variable block sizes (2–4 patients/block),
and randomization will be stratified by site to account
for site-specific practice variation. The randomization
system will assign each randomized patient a unique
study ID number. The site pharmacist will match the
ID number to a treatment arm on a hard-copy
randomization list and dispense the appropriate treat-
ment. At sites where a research pharmacist is not
Table 1 World Health Organization trial registration data set: structured summary
Data category Information
Primary registry, trial identifying number ClinicalTrials.gov identifier NCT02044159
Date of registration in primary registry January 21, 2014
Secondary identifying numbers CHEO REB 14/05E
Protocol version Version 5, May 7, 2015
Sources of monetary support Canadian Institutes of Health Research Operating Grant
Primary sponsor Investigator-initiated study
Kusum Menon (KM)




Phone: 613-737-7600 ext. 2538
Email: menon@cheo.on.ca
Secondary sponsor Children’s Hospital of Eastern Ontario Research Institute
Contact for public queries KM, Pediatric Critical Care, Children’s Hospital of Eastern Ontario, Ottawa, Canada
Contact for scientific queries KM, Pediatric Critical Care, Children’s Hospital of Eastern Ontario, Ottawa, Canada
Public title Steroids in Fluid and Vasoactive Infusion Dependent Shock (STRIPES) pilot study
Scientific title Steroids in Fluid and Vasoactive Infusion Dependent Shock (STRIPES) pilot study
Country of recruitment Canada, multi- academic center (7) study
Health problem under investigation Efficacy and safety of hydrocortisone as a treatment of fluid and vasoactive infusion dependent shock
Key inclusion and exclusion criteria Eligible for study: started on a vasoactive infusion within 24 h of PICU admission
Inclusion criteria: newborn to 17 years of age, receiving vasoactive infusions for 1–6 h
Exclusion criteria: known or suspected hypothalamic, pituitary or adrenal disease; currently receiving
steroids for shock prior to randomization; are expected to have treatment withdrawn; post cardiac
surgery; primary cardiogenic shock, spinal shock, hemorrhagic, or hypovolemic shock proven
or strongly suspected; previously enrolled in the STRIPES study; steroids started for reasons other
than shock; no longer on inotropes at the time of randomization or first dose of study drug; or
physician refusal
Study type Pragmatic, multi-center, double-blind, pilot randomized controlled trial
Date of first enrollment September 4, 2014
Target sample size 72
Recruitment status Recruiting as of July 2014
Primary outcome Patient accrual rate over a 1-year recruitment period
Key secondary outcomes Adherence to the study protocol; frequency of open-label corticosteroid use and the clinical
characteristic of patients in whom open-label corticosteroids are used; incidence of mortality
and adverse events; time to discontinuation of inotropes; and the feasibility of mechanistic
blood sampling
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available on evenings and weekends, numbered medica-
tion kits will be accessible to research assistants in a
temperature-controlled refrigerator.
Allocation concealment and blinding
All study personnel (the overall study research coordin-
ator, research assistants, site investigators, Principal Inves-
tigator, co-investigators, data management personnel, and
statisticians), members of the health care team (treating
physicians, bedside nurses, and clinical pharmacists if dif-
ferent from the research pharmacist), and patients/families
will be blinded to the study group assignment. To main-
tain blinding, the randomization lists will only be access-
ible to the Methods Centre at the Ottawa Hospital
Research Institute and to the site pharmacies. The active
drug and the placebo (hydrocortisone and normal saline)
will be identical in appearance, volume, and smell as
hydrocortisone is made up in normal saline and dissolves
completely with no visible precipitate.
Study procedures are in place to address the possibility
of requests by treating physicians to unblind group allo-
cation for a particular patient. The treating physician
will notify the site investigator, who will ask the phar-
macy to reveal to which group the patient has been allo-
cated. We expect that the request to unblind patients
will be minimal as treating physicians will be permitted
to use open-label corticosteroids if they judge that this is
clinically necessary.
Interventions
Patients randomized to the hydrocortisone group will
receive a 2-mg/kg hydrocortisone intravenous (IV) bolus
at the time of enrollment followed by 1 mg/kg of hydro-
cortisone administered intravenously every 6 h (q6h)
until the patient has not had an escalation in therapy (as
defined by an increase in their vasoactive infusions or a
fluid bolus such as normal saline, Ringer’s lactate, albu-
min, or any other blood product) for at least 12 h. Once
these criteria are met, hydrocortisone will be reduced to
1 mg/kg every 8 h and continue at this frequency until
all vasoactive infusions have been discontinued for 12 h.
The weaning of hydrocortisone from q6h to q8h is
important in order to ensure the patient receives the
minimum amount of corticosteroid that is necessary for
hemodynamic stability so as to prevent adrenal suppres-
sion and potential adverse events. If, following the initial
hydrocortisone wean, the patient requires fluid boluses
and/or an increase in their vasoactive infusion(s), the
dosing frequency will return to every 6 h until the pa-
tient meets stability criteria again. Hydrocortisone will
be continued for a maximum of 7 days to minimize the
incidence of adrenal suppression. In keeping with the
pragmatic nature of this trial, all other patient man-
agement, including (but not limited to) use of intub-
ation, mechanical ventilation, sedation and analgesia,
hemodynamic triggers and endpoints, red cell transfu-
sions, antibiotics, and fluid boluses, will be left to the
discretion of the treating physician. The Surviving
Sepsis Campaign guidelines flowchart (see [31]) will
be attached to the study protocol for easy reference
by the treating physician, but its use will not be
mandated; however, the use of vasoactive infusions
and other therapies will be recorded.
Although we will discourage physicians from using
open-label corticosteroids and carefully record any such
occurrence, we will not refer to open-label use as a
protocol violation so as not to deter enrollment and to
encourage buy-in. In the event that the patient does not
receive the full treatment as per protocol, data collection
will continue.
Patients in the control group will receive a placebo
consisting of normal saline equivalent in volume to the
appropriate dose of hydrocortisone. The remainder of
the protocol will be as per the experimental group.
Blood sampling
Although the primary focus of this pilot study is to
determine the feasibility of conducting a clinical outcome-
based RCT of hydrocortisone versus placebo in shock, this
pilot also provides an excellent opportunity to perform
some exploratory mechanistic studies. Given the expertise
of our team, the specific substudies we chose to conduct
include the utility of free cortisol versus total cortisol
Table 2 STRIPES pilot study inclusion and exclusion criteria
Inclusion criteria
1. Children newborn to 17 years and on any dose of any vasoactive
infusion for between 1 to 6 h
Exclusion criteria
1. Known or suspected hypothalamic, pituitary, or adrenal disease
2. Currently receiving steroids for shock prior to randomization
3. Expected to have life support withdrawn
4. Premature infants (<38 weeks corrected gestational age)
5. Pregnancy
6. Post cardiac surgery
7. First dose of vasoactive infusion administered >24 h after PICU
admission
8. No longer on vasoactive infusion at time of enrollment and/or
expected to no longer be on vasoactive infusion at time first dose
of study drug due
9. Primary cardiogenic shock suspected or proven
10. Spinal shock suspected or proven
11. Hemorrhagic or hypovolemic shock suspected or proven
12. Previously enrolled in STRIPES
13. Started on vasoactive infusion for reasons not related to shock
14. Physician refusal
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Patient in shock within 24 hours of PICU 
admission
Inotropes initiated
Patient on inotropes for ≥1 hour and ≤6
hours
Patient screened for eligibility to determine 
if any exclusion criteria are present
Exclusion criteria present
Patient not eligible
No exclusion criteria present
Patient is eligible
Deferred consent model used 
Consent to continue in study 
sought as soon as possible 
If denied, patient is 
withdrawn
Deferred consent model not used 
Informed consent sought from legal guardian
Consent denied
Patient not eligible for 
randomization
Patient randomized within 6 hours 
of initiation of inotropes
Consent obtained
Hydrocortisone 2mg/kg
within 8 hours of 
initiation of inotropes
Placebo equivalent volume
within 8 hours of initiation
of inotropes
Hydrocortisone 1mg/kg
q6h until there has been 
no escalation in therapy 
for at least 12 hours
Placebo equivalent volume
Placebo equivalent volume Hydrocortisone 1mg/kg
q8h until patient has 
been off inotropes for at 
least 12 hours
If access for bloodwork or 
venipuncture done as part of clinical 
care, then send blood for:
• Free cortisol and total cortisol
• Stratification biomarkers
• 25OHD and 1,25 OHD
If access not available, but becomes 
available within 24 hours of
enrolment then send the last two 
samples
D/C study drug
Fig. 1 Protocol flow diagram for the STRIPES pilot study
O’Hearn et al. Trials  (2016) 17:238 Page 5 of 10
measurements, the ability of stratification biomarkers to
predict severity of illness, and the interaction between
the adrenal and vitamin D axes. More detail on these
substudies is provided in Additional file 2. Patients
with existing venous or arterial access and who are
undergoing a venipuncture for clinical blood work
before the first dose of study drug will have a blood
sample sent for analysis of free cortisol and total
cortisol, mortality risk stratification biomarkers, 25-
hydroxyvitamin D, and 1,25-hydroxyvitamin D. If access
for bloodwork is not available before the study drug is
initiated, but it becomes available within the first 24 h of
enrollment, a research sample will be sent for analysis
of stratification biomarkers, 25-hydroxyvitamin D, and
1,25-dihydroxyvitamin D only.
Outcomes
This is a pilot study; hence, the primary outcome is
feasibility, defined by accrual rate over 1 year. Our goal
is to recruit 72 patients within this time frame. However,
we will consider patient accrual to be adequate if we
recruit 60 patients from seven sites within 1 year. We
will also assess potential barriers to recruitment, includ-
ing lack of a deferred consent model, physician- and
guardian-related consent issues, availability of research
personnel, and the narrow recruitment window (6 h
from the initiation of vasoactive infusion). The second-
ary outcomes are summarized in Table 3; they include
the frequency of open-label steroid use, adverse events
related to corticosteroid use, time to discontinuation of
vasoactive infusions, incidence of mortality, and the
feasibility of blood sampling.
An RCT design is necessary to investigate our feasibil-
ity outcomes. The main goal of our study is to determine
the feasibility of conducting an RCT of hydrocortisone
versus placebo in pediatric septic shock as determined
by our ability to recruit patients into this trial. There
were several issues with potential recruitment that we
identified a priori that could only be tested through a
pilot RCT. Firstly, we identified that some centers could
have issues with recruiting patients into such a trial be-
cause they wished to administer steroids. Thus, determin-
ing whether or not they will actually randomize patients is
of paramount importance. Secondly, the study has a very
narrow recruitment window; therefore, we need to deter-
mine whether or not sites can randomize patients, obtain
the study drug, and administer the first dose within 8 h of
patient eligibility. This can only be tested by piloting the
randomization procedures. Finally, we are proposing a
novel deferred consent model for obtaining informed
consent. It will be very important to understand the
acceptability of this model for families in the context of a
randomized double-blind controlled trial.
A randomized controlled trial design is also necessary
to determine if physicians will administer open-label
steroids to patients if they worsen. It would be important
to determine if the use of open-label steroids would be
different between the two groups: Does early administra-
tion of steroids lead to physiologic improvements that
remove the necessity for open-label steroids?
Sample size
Based on data from our multi-center retrospective study,
we expect to enroll 72 patients. This target takes into
account the frequency of septic shock at each center,
along with the projected consent rate at each center.
This target number will: (1) allow us to assess our feasi-
bility objectives over a reasonable time period (1 year),
(2) allow each center to recruit between 6 and 24
patients, and (3) allow us to test the acceptability of our
eligibility criteria as well as open-label steroid use at
seven sites and with exposure to 50 different clinicians.
Given that this is a pilot study, we will consider recruit-
ment to be feasible if we achieve 80 % (60 patients) of our
target enrollment, a threshold commonly used in critical
care pilot studies. With 60 patients, we will have the
Table 3 Secondary outcomes for the STRIPES pilot study
Outcome Metric for analysis
Adherence to the protocol: We will consider adherence adequate if each of goals a through c is met in 80 %
of enrolled patients:
a. Time to administration of the first dose of study drug
b. Weaning of drug to q8h when hemodynamically stable
c. Discontinuation of drug when off all vasoactive infusions
a. Goal is <8 h from starting vasoactive medication
b. Goal is to wean within 12 h of no escalation of therapy
c. Goal is to discontinue between 12 and 18 h after vasoactive infusion stopped
Open-label steroid use We will consider the number of patients started on open-label steroids to be




a. Severe bleeding, secondary infections, and use of insulin infusions
b. Time to discontinuation of vasoactive infusion and incidence of mortality
Successful blood sampling and processing The percentage of patients from whom blood samples are sent
The percentage of samples sent that are successfully received and analyzed in their
respective labs
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ability to detect an adherence rate of 80 ± 10 % (meaning
80 ± 10 % of study patients will have fewer than 10 %
of monitored values as violations). The median time
to discontinuation of vasoactive agents observed in
this pilot study will be used to better estimate the
sample size needed for the full RCT.
Recruitment, compliance, and follow-up
All ED and PICU staff will be made aware of the study
through information sessions, posters in the ED and
PICU, weekly rounds with the research assistants, and
weekly emails. Monthly recruitment newsletters will be
sent to all sites to encourage enrollment and discuss
commonly encountered questions.
Compliance is likely to be high as the protocol is
simple and closely follows usual clinical practice in these
patients. This assumption is based on experience from
the Vasopressin in Pediatric Shock (VIP) study, which
randomized children in vasodilatory shock to vasopres-
sin or placebo and used many of the same sites and
investigators as our current proposal. Despite utilizing a
more complex protocol and recruiting sicker patients,
the VIP trial had only two protocol violations and was
successfully completed [32]. It is possible that open-label
corticosteroid use will be higher than the anticipated
10 % rate. However, we will collect specific data on the
circumstances in which this occurs in order to provide
more targeted education around this practice in the full
trial. Follow-up for the STRIPES pilot study ends at
hospital discharge or death. Therefore, we anticipate a
follow-up rate of 100 %.
Data collection and management
Data for each patient will be entered by trained research
assistants at each site and managed using an electronic
data capture tool, REDCap (Research Electronic Data
Capture), which will be hosted at the Children’s Hospital
of Eastern Ontario (CHEO) Clinical Research Unit [33].
REDCap is a secure, web-based application designed to
support data collection for research studies. Predefined
ranges for all data values will be set up in this applica-
tion to allow data entry personnel to validate data as
soon as it is entered and send data queries immediately.
Missing data will be similarly managed. For each en-
rolled patient, we will collect information from their
medical chart. Data will be entered into the case report
form (CRF, available on the STRIPES study website at
http://stripes.ccctg.ca/Home.aspx), and each record will
be identified only by study ID number to maintain
patient confidentiality. The following information will be
collected: demographic information, inotrope use, dur-
ation of mechanical ventilation, PRISM III and PELOD-
2 scores, insulin infusion use, gastrointestinal bleeding,
laboratory results, and basic resource utilization data.
Research assistants at each site will maintain a daily
paper screening log which will track every patient who is
started on a vasoactive infusion within their first 24 h of
PICU admission. When eligible patients are not enrolled,
we will classify the reason for non-enrollment as: (1)
refusal from patient and/or legal guardian (specifying
reason for refusal, if provided); (2) inability to contact
legal guardian in centers without deferred consent (spe-
cifying reason contact could not be made, if available);
(3) refusal from attending physician (specifying reason
for refusal); (4) lack of availability of the research assist-
ant; and (5) patient died before enrollment. We will also
record age, gender, and PRISM III scores for these
patients to determine if there are demographic differences
between eligible patients who are and are not enrolled. A
data management plan has been developed for the study
and is available on the STRIPES study website.
Statistical analysis
To meet the feasibility objectives of this pilot RCT, we
have planned descriptive analyses. We will present recruit-
ment rate, feasibility events, and open-label corticosteroid
use as proportions with 95 % confidence intervals. Re-
cruitment feasibility will be defined as achieving 80 % of
our target goal of 72 patients. We will present continuous
data as means and standard deviations, or medians and
interquartile ranges, as appropriate. Patients who are
randomized but withdraw or do not provide consent will
be analyzed using intention to treat if they provided
consent to keep their data.
Monitoring
The Data Monitoring and Safety Committee (DMSC) will
include a senior biostatistician, a pediatric endocrinologist,
and a pediatric intensive care specialist. The DMSC will
review all serious adverse events (SAEs) — any serious
events that the attending site intensivist believes may be
directly related to enrollment in this trial. Study sites will
report all SAEs to the Coordinating Center within 24 h of
becoming aware of the event. The site will fill out a SAE
report and provide any related clinical documentation
(de-identified) to the Coordinating Center for distribution
to the Principal Investigator and the DMSC chair. The
DMSC chair will determine whether immediate input
from other DMSC members is required before sending
the final DMSC determination to the Principal Investi-
gator. There will be no stopping rules; however, the
DMSC can make recommendations to the Principal
Investigator, who will communicate back to the Steer-
ing Committee at the end of the trial regarding any
safety concerns for the full trial. We will provide the
DMSC with analyses by group (blinded as group A and B)
at the completion of this pilot RCT. These analyses will
include relative rates of gastrointestinal bleeding,
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infections, and hospital mortality. Due to the small sample
size and short duration of this pilot trial, we have not
planned for any interim analyses.
The study coordinator will monitor the sites at study
initiation, midway through the recruitment period, and
at study close-out to ensure compliance with the proto-
col and to troubleshoot any barriers to recruitment. Data
entered into the electronic CRF will be verified on an
ongoing basis, and the Data Quality function in REDCap
will be used to send and resolve data queries where
required. Given the pilot nature of this study, a formal
audit of the trial will not be conducted.
Ethics
Research ethics board approval has been obtained from all
participating centers. Protocol amendments will be com-
municated as necessary to those involved with the study.
An application for deferred consent was approved at five
sites (Ottawa, Vancouver, Calgary, Hamilton, and Halifax).
Deferred consent was not possible in Quebec as per
provincial legislation. The study protocol was approved by
the following ethics review boards: the Children’s Hospital
of Eastern Ontario Research Ethics Board, Ottawa, On-
tario (reference number: 14/05E); the Hamilton Integrated
Research Ethics Board, Hamilton, Ontario (reference
number: 14–636); Comité d’éthique de la recherche à
CHU Sainte-Justine, Montreal, Quebec (reference num-
ber: 3990); the Montreal Children’s Hospital Research Eth-
ics Board, Montreal, Quebec (reference number: 14-121-
PED); the Conjoint Health Research Ethics Board of the
University of Calgary, Calgary, Alberta (reference number:
REB14-0606); the University of British Columbia Chil-
dren’s and Women’s Research Ethics Board, Vancouver,
British Columbia (reference number: H14-01109); and
the IWK Research Ethics Board in Halifax, Nova Scotia
(reference number: 1017182).
Close-out
All data and source documentation will be stored in
a locked, secure storage facility for 25 years from
the time of study close-out. The study drug will be
destroyed and reconciled at each site according to
the procedures of the site pharmacy. Only the Prin-
cipal Investigator, the research coordinator, or their
delegate will have access to the data once the study
is closed.
Discussion
We recently published a systematic review [6] on the
use of corticosteroids in pediatric shock. The review
concluded that “The literature on the use of steroids in
pediatric shock is limited in amount, methodological
quality and demonstrates conflicting results. The limited
evidence on which current guidelines are based strongly
supports the need for a well-designed, pragmatic ran-
domized controlled trial on the use of steroids in
pediatric shock to inform future guidelines.” There are
two small RCTs currently listed on www.clinicaltrials.gov
(NCT01047670, NCT00732277); however, neither study
has been updated since 2010. Given their size and
unclear recruitment status, it is unlikely that either of
the latter two trials will be able to answer the ques-
tion of whether corticosteroids improve outcomes in
pediatric shock.
This study is the first step towards a large RCT to
provide clarity on the use of corticosteroids in critically
ill children with shock. Results of the STRIPES pilot
study will provide essential feasibility data for planning
and conducting a larger, multi-center trial that will help
to establish the role of corticosteroids in children with
fluid and vasoactive infusion dependent shock. Our goal
is to enroll a minimum of 60 patients at seven sites over
a 1-year period. Failure to do so will prompt us to
modify our plans for a future trial. If our recruitment
rate is as anticipated or better, we will not modify
eligibility criteria. If our recruitment rate is marginal
(that is, barely achieves our goals), we will examine the
number of patients excluded on the basis of each exclu-
sion criterion, and will reconsider the necessity for any
criterion that has resulted in a large number of excluded
patients. We will record the number of eligible non-
randomized patients and reasons for non-enrollment,
and on the basis of these results, we will consider deter-
rents to randomization and methods to enhance enroll-
ment of eligible patients. If the pilot study demonstrates
feasibility, no major protocol changes are needed, and
no safety concerns are raised by the STRIPES DMSC,
then the results of the pilot study will be rolled into
the full trial. However, if any of the above criteria are
not met, then the protocol will be re-evaluated and
the feasibility results of the pilot study published
independently.
Trial status
Recruitment for the STRIPES pilot study started at
the Coordinating Centre (Children's Hospital of East-
ern Ontario, Ottawa) in July 2014. Four of the six
other Canadian PICUs initiated recruitment between
December 2014 and February 2015. The remaining
two sites will commence recruitment in July of 2015
and in the fall of 2015, respectively. The first patient
was enrolled on September 4, 2014, and recruitment is
expected to continue until March of 2016.
Additional files
Additional file 1: SPIRIT Checklist. (DOC 143 kb)
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Additional file 2: Summary of mechanistic studies. This table
summarizes the mechanistic studies that will be performed as part of the
STRIPES pilot study, including the rationale, timing, and amount of blood
sample required for each test. (PDF 202 kb)
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